AstraZeneca PLC's faith in the benefits of combining the firm's checkpoint inhibitor Imfinzi with its experimental anti-CTLA-4 monoclonal antibody tremelimumab has been shaken once again as it failed to improve overall survival in patients with late-stage small cell lung cancer (SCLC), although Imfinzi monotherapy did improve OS.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?